<DOC>
	<DOCNO>NCT00825487</DOCNO>
	<brief_summary>This open-label , dose escalation study intravenous ARQ 621 administer patient late-stage solid tumor hematologic malignancy .</brief_summary>
	<brief_title>Dose Escalation Study ARQ 621 Adult Patients With Metastatic Solid Tumors Hematologic Malignancies</brief_title>
	<detailed_description>The study design explore safety , tolerability pharmacokinetics ARQ 621 define recommend phase 2 ( RP2D ) dose ARQ 621.Treatment initiate dose level 10 mg/m^2 IV infusion hour weekly 4-week ( 28 day ) consecutive continuous cycle . ARQ 621 infuse IV two hour dose 200 mg/m^2 high ( cohort 8 ) . All cycle therapy consist patient take ARQ 621 intravenously weekly 4 week . Dose escalation proceed initially double ( cohort 2 3 ) subsequently modify Fibonacci scheme . Dose escalation perform use 3-6 patient cohort . In cohort , single dose limit toxicity ( DLT ) experience among patient 1-3 , dose cohort expand six patient . The maximum tolerated dose ( MTD ) define dose level great 1/6 patient experience DLT . Once MTD identify , additional 20 patient ( type malignancy determine later date study investigator clarify study amendment ) may treat MTD ARQ 621 . If MTD identify initial 10 dosing cohort , dose escalation proceed manner define subsequent amendment purpose determine RP2D ARQ 621 .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Signed write informed consent must obtain document accord International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) , local regulatory requirement , permission use private health information accordance Health Insurance Portability Accountability Act ( HIPPA ) prior studyspecific screening procedures A histologically cytologically confirm metastatic solid tumor refractory/relapsed hematologic malignancy Have life expectancy least 12 week ≥18 year age Measurable disease define : Solid Tumors : Response Evaluation Criteria Solid Tumors Multiple Myeloma ( MM ) : International Uniform Response Criteria , least one following : Monoclonal protein plasma ≥0.5 g/dL Monoclonal protein urine ≥0.2 g/24 hr urine collection Serum immunoglobulin free light chain ( FLC ) ≥100 mg/L ( 10 mg/dL ) abnormal serum immunoglobulin kappa lambda FLC ratio Malignant Lymphoma ( ML ) : International Working Group Response Criteria At least one site disease ≥2 cm long diameter ( lesion ≥1 cm consider PET positive ) Chronic Lymphocytic Leukemia ( CLL ) : NCI Working Group Guidelines Lymphocytosis ( 5 x 10^9 /L ) Bcell marker ( CD19 , CD20 , CD23 ) + CD5 Highrisk characteristic ( hemoglobin &lt; 10g/dL OR platelet &lt; 100 x 10^9 /L ) Acute Myelogenous Leukemia ( AML ) Acute Lymphoblastic Leukemia ( ALL ) : patient bone marrow peripheral blast count ≥20 % Acute Promyelocytic Leukemia ( APML ) : patient must refractory alltrans retinoic acid ( ATRA ) arsenic trioxide Chronic Myelogenous Leukemia ( CML ) : patient blast crisis ( bone marrow peripheral blast count ≥20 % ) may include refractory prior therapy therapy investigator deem high priority ( example , BCRABL inhibitor imatinib mesylate [ Gleevec ] , nilotinib [ Tasigna ] , dasatinib [ Sprycel ] ) ECOG performance status ≤2 Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 30 day last ARQ 621 dose Females childbearing potential must negative serum pregnancy test Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤2.5 × upper limit normal ( ULN ) ≤5.0 × ULN metastatic liver disease Hemoglobin ( Hgb ) ≥10 g/dL ( except case consider related hematologic malignancy ) Total bilirubin ≤1.5 × ULN Creatinine ≤1.5 x ULN ( ≤2.0 x ULN case consider related multiple myeloma ) Absolute neutrophil count ≥1.5 x 10^9/L ( except case consider related hematologic malignancy ) Platelets ≥100 x 10^9/L ( except case consider related hematologic malignancy ) Patients hematologic malignancy progress follow least two prior treatment regimen Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within four week first dose In case hematologic malignancy , 4week recovery prior anticancer treatment require , however patient must recover prior treatmentrelated nonhematological toxicity grade 2 less When require supportive care corticosteroid hydroxyurea may use Surgery within four week prior first dose Known untreated brain metastasis leptomeningeal disease Patients solid tumor treat brain metastasis show stable disease least 8 week prior enrollment allow Pregnant breastfeed Uncontrolled concurrent illness include , limited ongoing active symptomatic infection require systemic therapy , clinically significant nonhealing heal wound , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , significant pulmonary disease ( shortness breath rest mild exertion ) , uncontrolled infection psychiatric illness/social situation would limit compliance study requirement Patients history Thrombotic thrombocytopenic purpura ( TTP ) Hemolyticuremic syndrome ( HUS ) HUS spectrum exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>metastatic</keyword>
	<keyword>hematologic</keyword>
	<keyword>malignancy</keyword>
	<keyword>multiple</keyword>
	<keyword>myeloma</keyword>
	<keyword>malignant</keyword>
	<keyword>lymphoma</keyword>
	<keyword>chronic</keyword>
	<keyword>lymphocytic</keyword>
	<keyword>leukemia</keyword>
	<keyword>acute</keyword>
	<keyword>myelogenous</keyword>
	<keyword>promyelocytic</keyword>
	<keyword>dose escalation</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>tumor</keyword>
	<keyword>PK</keyword>
</DOC>